フィルゴチニブはメトトレキサートに反応性不十分な活動性関節リウマチおよび尋常性乾癬患者における末梢血の炎症関連タンパクを修飾する
Rheumatol Ther. 2023;10(5):1335–1348 doi 10.1007/s40744-023-00583-9
This study by Tanaka, et al. shows that filgotinib reduces peripheral protein biomarkers associated with JAK/STAT signalling, inflammatory signalling, immune cell migration, and bone resorption in RA patients. Notably, filgotinib 200 mg significantly reduced IL-6, TNF, CXCL13 levels as early as Week 4.
Data were taken from FINCH1, a global, Phase 3, double-blind, active-controlled study. Biomarkers were analysed at baseline, Week 4, and Week 12. Patients were randomised to filgotinib 100 mg, filgotinib 200 mg, adalimumab 40 mg, or placebo.
Keywords:
